Conclusion: the study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.
Results: Reduced QoL was found in patients with adrenal incidentaloma as compared to controls. Dimensions of QoL that were notably affected included mobility (p=0.03), performance of usual activities (p=0.002) and anxiety/depression (p=0.04) as evaluated using the EQ-5D; physical functioning (p<0.001), physical role (p<0.001), general health (p<0.001), vitality (p=0.001), social functioning (p=0.001) and emotional role (p<0.001)as evaluated using the SF-36; and physical fatigue (p=0.04) as assessed using the MFI-20questionnaire. In addition, perceived health on a visual analogue scale was also significantly lower in patients than in controls (64.8±19.2 vs. 77.1±15.1; p<0.001).
Conclusion:Patients with adrenal incidentaloma reported reduced QoL and a higher level of physical fatigue compared to age-and sex-matched controls. This subject will benefit from further studies comparing QoL outcomes of laparoscopic adrenalectomy vs. no treatment in patients with adrenal incidentaloma.
Summary
Alemtuzumab is a monoclonal antibody targeting CD52, increasingly used as induction therapy after transplantation. The aim of this study was to analyze the outcomes of alemtuzumab induction therapy followed by a low‐dose maintenance immunosuppression in a large single‐center cohort of lung transplant recipients. All patients, who received alemtuzumab induction followed by a low‐dose maintenance immunosuppression were included in the analysis. Short‐ and long‐term outcomes were analyzed. 721 lung transplant recipients, transplanted between January 2008 and June 2019, were included in this retrospective study. Freedom from higher‐grade ACR at 1, 5, and 10 years was 98%, 96%, and 96%, respectively. Thirty‐nine patients (5%) developed clinical AMR. Twenty‐one percent of patients developed high‐grade CKD. A total of 1488 infections were recorded. Sixteen percent were diagnosed within the first 3 months. Sixty‐two patients (9%) developed a malignancy during follow‐up. Freedom from CLAD at 1, 5, and 10 years was 94%, 72%, and 53%, respectively. Overall survival rates at 1, 5, and 10 years were 85%, 71%, and 61%, respectively. Alemtuzumab induction combined with a low‐dose tacrolimus protocol is safe and associated with low rates of acute and chronic rejection, as well as an excellent long‐term survival.
Background: It is well known that acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with increased morbidity, readmission rates and mortality, but few studies report rehospitalization and mortality rate after severe AECOPD treated in intensive care unit (ICU). The aim of our study was to assess two year readmission rates and mortality in AECOPD patients treated in ICU and to identify determinants of these outcomes. Methods: 55 patients (35 men) mean age 68.1 (±10.5) years successfully treated in respiratory ICU due to AECOPD and discharged from hospital were included in the study. Patients demographics, hematology, biochemistry and arterial blood gases on the first treating day were recorded. Results: During the median follow-up of 2.4 years, 29 (46.8%) patients had one or more readmissions due to AECOPD. The average number of readmissions was 1.2. Significant predictors for the time to next hospitalization were initial PaCO2, fibrinogen, proteins and alpha 2 globulins (p=0.001 for the overall model fit). Significant predictors for the number of readmissions were: age at admission, neutrophil count, serum sodium, bilirubin, coronary artery disease (p<0.001 for the overall model fit). During the follow-up, 21 (38.2%) patients died. Significant predictors for survival time after incident hospitalization were: BMI, monocyte count, serum LDH, cancer and hypertension (p<0.001 for the overall model fit). Conclusion: Our study suggests that patient age, comorbidity, BMI and certain biochemistry parameters are potential predictors of readmission and poor outcome after AECOPD treated in ICU. Further studies are needed to verify our findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.